Vita 34 Reports Revenue Growth and Cash Increase in Q3 2024

Vita 34 AG, Europe's leading cell bank, reported a rise in revenue, profitability, and cash generation for Q3 2024. Revenues increased by 6.3% year-on-year, reaching EUR 60.3 million. EBITDA also saw significant growth, up by 77.5% to EUR 6.4 million, bolstered by one-time effects, with the margin reaching 10.6%.

The company reported strong operating cash flow growth of 61.1%, amounting to EUR 7.8 million. Despite challenges in key markets such as Germany and Portugal, regions like Switzerland and Spain showed promising developments.

Vita 34 plans to expand placenta tissue banking across Europe following successful launches in Poland and Romania. The Management Board maintains its revenue guidance for 2024 between EUR 81 million to EUR 88 million and expects EBITDA to be between EUR 6.5 million and EUR 8.0 million.